key: cord-1019302-stnzcc67
authors: Guo, Xueyang; Kazanova, Alexandra; Thurmond, Stephanie; Saragovi, H. Uri; Rudd, Christopher E.
title: Effective chimeric antigen receptor T-cells (CAR-Ts) against SARS-CoV-2
date: 2021-10-16
journal: iScience
DOI: 10.1016/j.isci.2021.103295
sha: 37a6e46051bf90d3213666f5fb24509c4f441766
doc_id: 1019302
cord_uid: stnzcc67

Current therapies to treat coronavirus disease 2019 (COVID-19) involve vaccines against the spike (S) protein S1 of SARS-CoV-2. Here, we outline an alternative approach involving chimeric antigen receptors (CARs) in T-cells (CAR-Ts). CAR-T recognition of the SARS-CoV-2 (RBD) peptide induced ribosomal protein S6 phosphorylation, the increased expression of activation antigen, CD69 and effectors, interferon-γ, granzyme B, perforin and Fas-ligand on overlapping subsets of CAR-Ts. CAR-Ts further showed potent in vitro killing of target cells loaded with RBD, S1 peptide or expressing the S1 protein. The efficacy of killing varied with different sized hinge regions, while time-lapse microscopy showed CAR-T cluster formation around RBD expressing targets. Cytolysis of targets was mediated primarily by the GZMB/perforin pathway. Lastly, we showed in vivo killing of S1-expressing cells by our SARS-CoV-2 CAR-T cells in mice. The successful generation of SARS-CoV-2 CAR-Ts represents a living vaccine approach for the treatment of COVID-19.

SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is a positive-sense singlestranded RNA virus and the cause of Coronavirus Disease 2019 . The severity of COVID-19 ranges from asymptomatic to mild self-limiting disease to severe and acute respiratory distress syndrome, neurological symptoms and death (Amanat and Krammer, 2020; Tay et al., 2020;  ter Meulen et al., 2006) .SARS-CoV-2 has an incubation period of 4-7 days before symptom onset, followed in some cases by the progression to severe disease (Peng et al., 2020) . Current therapies include the use of vaccines, convalescent plasma (Bloch et al., 2020) and re-purposed anti-viral treatments (Sarzi-Puttini et al., 2020) such as umifenovir and remdesivir/ribavirin (Jean et al., 2020) . Other approaches include the use of anti-IL-7, anti-IL-6 receptor antibodies and corticosteroids to dampen the inflammatory immune response (Russell et al., 2020; Tharmarajah et al., 2021) , and neutralizing monoclonal antibodies (mAbs) that bind to viral proteins that are critical for attachment and entry to mammalian cells (Altmann and Boyton, 2020) .

SARS-CoV-2 contains glycosylated spike (S) protein that facilitates viral attachment and cell entry and plays a critical role in the elicitation of the host immune response Meckiff et al., 2020; Premkumar et al., 2020; Varchetta et al., 2020; Wu et al., 2020) . It binds to the human angiotensin-converting enzyme 2 (ACE2) (Hoffmann et al., 2020b; Letko et al., 2020) which is the target of neutralizing antibodies (Cao et al., 2020; . The S protein forms a trimer where each monomer has two subunits (S1 and S2) separated by a cleavage site that is recognized by host cell proteases (Hoffmann et al., 2020a) . The S1 subunit is composed of the signal peptide (SP), N terminal domain (NTD), and receptor-binding domain (RBD), while the S2 subunit mediates membrane fusion. The RBD region is comprised of a 5-stranded anti-parallel betasheet between the β4-7 strands, is an extended insertion of short β5-6 strands. The extension carries the receptor-binding motif (RBM) that binds to the ACE2 receptor for entry into respiratory and digestive epithelial cells (Lan et al., 2020) .The three RBDs on the S protein head show conformational variability. In a closed conformation, the three RBDs are flat with the RBM occluded,

while in an open conformation, one or more RBDs lift to expose the RBM.

Severe COVID-19 patients show marked lymphopenia (Braun et al., 2020; Cizmecioglu et al., 2020) , increased pro-inflammatory cytokines and chemokines (Song et al., 2020) and high neutrophil levels in peripheral blood (Song et al., 2020; Varchetta et al., 2020) . Several studies have delineated aspects of cell immunity that determines disease outcomes (Braun et al., 2020; Campbell et al., 2020; Cheng et al., 2020; . Mild cases are associated with antibody J o u r n a l P r e -p r o o f the CD3-ζ chain or FcγRI protein into a single chimeric protein (Gross et al., 1989; Irving and Weiss, 1991) . The inclusion of intracellular motifs from the co-receptors CD28 and CD137 (4-1BB) extend the longevity of CAR-Ts (Jena et al., 2010; Maus and June, 2016) . CAR-Ts against relapsed acute lymphoblastic leukemia (ALL) have been associated with durable and sustained remissions for up to 24 months (Maude et al., 2014) . Severe cytokine-release syndrome in a minority of patients has been effectively treated with the anti-interleukin-6 receptor antibody, tocilizumab (Maude et al., 2014) . Three CAR-T based drugs (Breyanzi, Yescarta and Kymriah) have been approved by FDA, while other trials are presently underway in many academic medical centers (Sadelain et al., 2009 ).

In the case of SARS-CoV-2 Meckiff et al., 2020; Premkumar et al., 2020;  Rydyznski Moderbacher et al., 2020; , the induction of T-cell responses with different clonotypes indicates that SARS-CoV-2 derived peptides are likely available for recognition by appropriately designed CAR-Ts.

Surprisingly, although some CAR-Ts have been used to target hepatitis B virus envelope proteins in mice (Krebs et al., 2013) , the potential of CAR-T cells in the treatment of SARS-CoV-2 infection has not been explored (Seif et al., 2019) . In this study, we aimed to evaluate the feasibility of anti-SARS-CoV-2 CAR immunotherapy. We report the design and generation of different CAR-T cells that recognize and kill target cells loaded with the RBD region of the SARS-CoV-2 spike protein. The CAR-T cells could be phenotypically segregated into subsets expressing effector molecules, granzyme B, perforin, IFN-γ and FasL. Further, our work demonstrated that CAR-T cells against SARS-CoV-2 can be generated to elicit the in vitro and in vivo killing of RBD and S1 bearing target cells. This approach offers a new potential therapeutic approach for the treatment of COVID-19 for longer-term immunity. Future work will evaluate the efficacy of the different generated CAR-T cells for targeting the emerging threat caused by the different variants of SARS-CoV-2 Spike mutations.

A neutralizing antibody from a convalescent SARS patient termed CR3022 binds to the RBD region of both SARS-CoV-1 and SARS-CoV-2 spike protein (Tian et al., 2020) . Based on its sequence, the CR3022single chain variable fragment (scFv) was cloned into the bicistronic lentiviral vector (pHIV) followed by a Flag-tag sequence (DYKDDDDK), a hinge region, the CD28 transmembrane (TM) and intracellular domain and the CD3zeta () intracellular domain. CARs comprised of different hinge regions were generated that included either a 39 amino acid (aa) CD28hinge (CR3022-28Z) (residues 114-152), a 47 aa CD8alpha chain (residues 136-182) (CR3022-8a-28Z), a 119aa CH3 region hinge (residues 221-327) (CR3022-CH3-28Z) or a 229aa

IgG4 region hinge (residues 99-327) (CR3022-IgG4-28Z) (Fig. 1A) . As a control, we generated a CAR lacking an scFv region (Flag-28Z) and another with the scFv region of another monoclonal antibody termed CR3014 that reacts only with the RBD region of SARS-CoV-1 (CR3014-28Z). The n represents the number of single experiments, each from a different, individual donor. This measure applied to all figures in the paper. Each pHIV bicistronic lentiviral construct contained IRES-EGFP allowing for sorting and tracking the CAR-T cells.

To generate CAR-T cells, peripheral blood mononuclear cells (PBMCs) from a given donor were stimulated in vitro with anti-CD3 and anti-CD28 antibodies for 72 hours followed by spinoculation with lentiviral supernatant, further culturing for 4 days in X-VIVO15 serum-free medium followed by fluorescence-activated cell sorting (FACS) based on EGFP expression. Sorted CAR-T cells were then expanded in the same media supplemented with interleukin 2 (IL-2) for 2-3 weeks before their use in assays. Lentiviral driven expression of the CR3022-28Z, CR3022-8a-28Z, CR3022-CH3-28Z or CR3022-IgG4-28Z constructs was confirmed by EGFP expression (Fig.   1B) . The CR3022-CH3-28Z construct was routinely observed to be expressed at slightly lower levels than the other constructs. CAR expression on the surface of cells was confirmed by anti-Flag staining (Fig. 1B, SFig. 1 ). As a representative example, using CR3022-8a-28Z transduced cells, anti-Flag-APC and EGFP showed a similar heterogeneous viSNE pattern for CAR receptor expression. It could roughly be divided into populations of cells with high (island i), intermediate (island ii) and low-nil expression (island iii). The islands showed some overlap but defined a general trend of heterogeneity within the CAR-T population. Lastly, flow cytometric staining with anti-CD4 and anti-CD8 antibodies showed similar proportions of CD8+ and CD4+ cells amongst the CR3022-28Z, CR3022-8a-28Z, CR3022-CH3-28Z or CR3022-IgG4-28Z expressing CAR-J o u r n a l P r e -p r o o f Ts(SFig. 2) . These data showed that we were able to successfully transduce and maintain CAR-Ts.

We next assessed whether the RBD viral sequence presented on the surface of cells could activate the various CAR-Ts (Fig. 1c) . For this, 293-ACE2 cells were incubated with RBD peptide for 1 h (293-ACE2-RBD) prior to co-culturing with the CAR-Ts for 20h. The expression of hACE2 on the 293-ACE2 cells was confirmed by flow cytometry (SFig. 3). We initially examined changes in the expression of CD69 on CAR-Ts, a well-established activation marker on the surface of T-cells (Cibrian and Sanchez-Madrid, 2017) . Indeed, the co-culturing with 293-ACE2-RBD cells induced a marked increase in CD69 expression on the CR3022-28Z, CR3022-8a-28Z, CR3022-CH3-28Z or CR3022-IgG4-28Z CAR-Ts(left panel). As a negative control, neither Flag-28Znor CR3014-28Z CAR-T cells showed an increase in CD69. Similarly, standard flow cytometry profiles of a representative donor showed that 293-ACE2-RBD cells induced an increase in CD69expressionon each of the CR3022 CAR-Ts (upper right panel), while no increase was seen with incubation with 293-ACE2 cells lacking RBD (lower right panel). Further, in a titration experiment, CD69 expression was seen to increase in response to increasing concentrations of the RBD peptide pre-incubated with the 293-ACE2 cells (Fig. 1D) . In this case, we observed a titratable increase in the response to peptide as low as 10ng/ml. No response of the CR3014-28Z CAR-Ts was noted. The viability of cells in control and stimulation assays was similar. These data showed clearly that the presentation of the RBD peptide induced the expression of CD69 on the various CR3022 CAR-Ts.

We next assessed the heterogeneity of CD69 expression on CAR-Ts in more detail by viSNE and Cytobank analysis (Alfei et al., 2019; McLane et al., 2019) (Fig. 1E) . The CD69 population could be divided into three islands based on levels of expression (island i with the highest level, island ii intermediate levels (yellow/turquoise) and island iii with low-nil levels of CD69 (dark blue)). Importantly, the CD69 expression patterns changed in response to 293-ACE2-RBD cells with an increase in the percentage of CAR-Ts in island i relative to the total CAR-T population (from 35-40% to 65-70%; upper right panel) and in an increase in the relative mean fluorescent intensity (MFI) (from 1000 to 1800-2000; lower right panel) . No change in the expression of CD69 on Flag-28Z or CR3014-28Z was seen. By contrast, islands ii and iii showed much lower increase in expression and a decrease in their percent representation in the total CAR-T population (SFig. 4, left and right panels, respectively).

We also transduced Jurkat T-cells to express different CARs and monitored CD69 expression in response to RBD peptide presented by Vero cells (SFig. 5). Vero cells were co-incubated with J o u r n a l P r e -p r o o f 200 or 1000ng/ml RBD peptide. The CR3022 Jurkat cells, but not the Jurkat CR3014 cells, showed an increase in CD69 expression in response to peptide in the presence of Vero cells.

In addition, as a nearly intracellular signaling event, we assessed the phosphorylation of the ribosomal protein S6, a key signal transduction event that regulates cell division, protein translation and metabolism (Roux et al., 2007) (Fig. 1F) . As an example, CR3022-8a-28Z CAR-Ts were incubated with 293-ACE2 or 293-ACE2-RBD cells for 20min prior to the detection of S6 phosphorylation by flow cytometry. The incubation of CAR-Ts with 293-ACE2-RBDinduced S6 phosphorylation (ie. pS6) in the T cells, while no change was observed in response to incubation with the control, 293-ACE2 cells. As a positive control, the incubation of cells with PMA and ionomycin also increased S6 phosphorylation. These data indicate CAR-T engagement generated a key early intracellular signaling event needed for cell proliferation.

Lastly, the recognition of the RBD peptide led to the downregulation of the CARs from the surface of cells (Fig. 1G) .CAR downregulation has been previously reported and in the case of other receptors, due to receptor-mediated engagement (Monjas et al., 2004; San Jose et al., 2000; Schneider et al., 1999) .The 20hours incubation period was sufficient time to allow for both the induction of signaling and the subsequent downregulation of the receptors .In agreement, the CR3022-28Z CAR receptors were downregulated with increasing RBD peptide concentrations in a manner that inversely mirrored the induction of CD69 expression. As a control, no titratable response of the CR3014-28Z CAR-T was observed. This data confirmed that the CR3022 based CARs became engaged in a specific manner when presented with the RBD peptide.

We next assessed whether anti-SARS-CoV-2CAR-Ts were cytolytic in killing SARS-CoV-2 RBD/S1 loaded cells (Fig. 2) . CAR-Ts were co-cultured with different ratios (20:1, 10:1, 5:1) of 293-ACE2-RBD/CAR-Ts for 5 hours for an assessment of killing. Each of the CR3022-based CAR-Ts was seen to kill the targets over various ratios ( Fig. 2A, left panel) . The presence of the RBD peptide on the 293-ACE2-RBD cells was confirmed by staining with anti-S1 and the CR3022 antibody (right panel). By contrast, as a negative control, T cells expressing Flag-28Z or CR3014-28Z failed to kill targets. Interestingly, CAR-Ts with different hinge regions showed differences in the efficiency of killing. The CD8a (CR3022-8a-28Z) and IgG4 (CR3022-IgG4-28Z) CAR-T expressing cells were the most effective killers followed by CR3022-28Z and CR3022-CH3-28Z.

Specificity was confirmed by CR3022 antibody blockade of killing (Fig. 2B) . 293-ACE2-RBD cells were incubated with CR3022, or the isotype control, at 37 0 C for 30min prior to the incubation with CAR-Ts. As shown in a representative experiment, the CR3022 antibody abrogated the killing J o u r n a l P r e -p r o o f of targets by the CR3022-8a-28Z and CR3022-IgG4-28Z CAR-Ts by 70-80 percent at various effector to target ratios. By contrast, the isotype control antibody had no effect on killing.

We also assessed the killing of 293-ACE2 target cells that had been pre-coated with the fulllength S1 peptide (Fig. 2C) . The presence of the S1 peptide on the cells was confirmed by staining with anti-S1 and the CR3022 antibody (right panel).CR3022-28Z, CR3022-8a-28Z and CR3022-IgG4-28Z CAR-Ts killed S1 peptide-loaded targets, albeit at lower levels ( Fig. 2C, left panel) . The CR3022-CH3-28Z CAR-T or the control CR3014-28Z CAR-T showed no killing. In this case, the CR3022-IgG4-28Z CAR-T was most effective. Overall, the CAR-Ts were less able to kill targets with only 10-30% for S1 peptide-coated cells compared to the 30-60% for RBD peptide-loaded target. This may be due to the mode of the specific RBD sequence presentation in the S1 protein as recognised by the CAR-Ts. Examples of the similar response of CAR-Ts from different donors to the RBD and S1 peptides are also shown in SFig. 6.

We next assessed SARS-CoV-2 CAR-T killing of NIH/3T3 cells that had been transduced to express the S1 protein ( Fig. 2D) . FACS profiles showed high levels of anti-S1 staining but a lower level of staining with the CR3022 antibody against the RBD peptide (lower panel). The reason for this difference is not clear but is likely related to the accessibility of the CR3022 epitope. The RBD is only accessible when at least two RBDs are open simultaneously (Yuan et al., 2020) and the frequency of the opening RBD is usually less than 30% (Wrobel et al., 2020) . Despite this, the various CR3022CAR-Ts were able to effectively kill targets (upper panel). Each of the CR3022-28Z, CR3022-8a-28Z, CR3022-CH3-28Z and CR3022-IgG4-28Z CAR-Ts killed 20-50 percent of target cells, dependent on the CAR-T to target ratio. In this assay, the CR3022-28Z CAR-T and the CR3022-IgG4-28Z CAR-T cells were the most effective.

Overall, these data showed that the CAR-Ts could be generated that recognise and kill targets coated with the RBD and S1 peptides or the S1 expressing NIH/3T3 cells. The CAR-Ts with different sized extracellular domains also varied in their killing efficacy of different target cells expressing the S1 protein. These CAR-T variants will enable the eventual testing efficacy against S1 variants.

The interaction of the CAR-T cells with the target cells was next examined using time-lapse live-cell microscopy (Fig. 3) . We analyzed the behaviour of CR3022-8a-28Z CAR-Ts co-cultured with the 293-ACE2 and 293-ACE2-RBD cells over 20 hours. The EGFP+ CAR-T cells were observed to be green due to EGFP expression, while the 293 cells were seen as red-orange colour due to the lentiviral transduction with mCherry. CR3022-8a-28Z formed clusters with 293-ACE2-RBD clusters within 30-60 minutes and were present for 10-15 hours followed by a slight reduction J o u r n a l P r e -p r o o f in clusters (Fig. 3A , also see SMovie 2). No clusters were seen with 293-ACE2 negative control cells (see SMovie 1). On average, there were 3-5 CAR-Ts in each cluster, although this varied depending on the timing of the analysis (Fig. 3B , also high magnification examples from two separate experiments in right panel). No clusters were seen with the 293-ACE2 cells alone. Cluster diameter also increased from 60 min to 10-12 hours with an average diameter of 30-40 um as assessed by ZEN Lite software (Fig. 3C) . Similarly, the surface area of the clusters increased from 500 to 1500um 2 over the same time-period (Fig. 3D ). An example of tracking between CR3022-8a-28Z CAR-Ts co-cultured with the 293-ACE2 pre-loaded with S1 peptide is also shown (SMovie 3).

Overall, these data confirmed that CR3022-8a-28Z CAR-Ts formed clusters with 293-ACE2-RBD targets dependent on the presence of the RBD/S1 peptides.

We next examined the inducible expression of immune effector molecules on the CAR-Ts.

The cytokine interferon-γ (IFN-γ) promotes differentiation into Th1 cells and the up-regulation of MHC antigens on dendritic cells (Schoenborn and Wilson, 2007) . Indeed, we observed an increase in IFN-γ expression in response to 293-ACE2-RBD cells on each of the CAR-Ts (Fig. 4A) . The highest increase in expression was seen on CR3022-28Z, CR3022-8a-28Z and CR3022-IgG4-28ZCAR-Ts. In a separate experiment, viSNE analysis showed that IFN-γ was already widely expressed on the majority of CAR-Ts after their expansion in IL-2 supplemented media ( Fig. 4B , see CAR-T alone; left panel) or after the incubation with 293-ACE2 cells (middle panel). A small increase in expression was observed after incubation with 293-ACE2 cells alone. However, in response to 293-ACE2-RBD cells, the CAR-Ts caused a major change in the distribution of expressing cells and expression intensity of IFN-γ as seen by viSNE. There was a loss of cells in islands ii and iii concurrent with an increase in the density of cells in island i. Each of the CR3022 based CAR-Ts showed a similar trend. In keeping with this, there was an increase in the percentage of IFN-γ+ cells in island i relative to the total CAR-T population (Fig. 4C ) as well as an increase in the relative MFI for IFN-γ in island i (Fig. 4D) . Lastly, viSNE analysis showed that the same island of cells with increased IFN-γ expression in island i also showed an increase in CD69 expression ( Fig.   4B , right panels). Overall, these data indicated that the recognition of the RBD peptide by CAR-Ts caused a major increase in the expression of IFN-γ in the same subset of cells that showed an increase in CD69 expression.

Given the ability of the various CAR-Ts to kill RBD or S1 bearing targets, we next assessed the expression of the cytolytic effectors, granzyme B (GZMB) and perforin (Fig. 5) . Both are key effector molecules that mediate the killing of targets (Kurschus and Jenne, 2010) . Perforin is a poreforming cytolytic protein that facilitates GZMB entry to kill target cells (Smyth et al., 1996) . Indeed, each CR3022 based CAR-T showed an increase in the level of expression of GZMB (Fig. 5A , upper panel) and perforin (Fig. 5A , lower panel) when incubated with RBD loaded target cells. CR3022-28Z, CR3022-8a-28Z and CR3022-IgG4-28Z CAR-Ts showed the highest level of GZMB and perforin expression. No increase was observed upon incubation with 293-ACE2 cells lacking RBD, or in the negative controls, Flag-28Z and CR3014-28Z.

Unlike in the case of IFN-γ, GZMB and perforin were expressed in a highly localised subset of CD69+ CAR-Ts within island i and ii (termed this subset as sub-island i-iia) (Fig. 5B) . A basal level of GZMB and perforin expression was seen in CAR-T cells incubated with 293-ACE2 cells.

Both molecules were expressed within the same subset of CAR-Ts. Incubation with 293-ACE2-RBD cells increased the expression of both proteins (lower panels). Each of the CAR-Ts showed a similar increase except for the CR3022-CH3-28Z which showed a more modest increase. An increase in the MFI for GZMB (Fig. 5C , upper panel) and for perforin (lower panel) was observed. No increase in GZMB in islands ii and iii was observed (upper panel), while a modest increase in perforin expression in the same islands was seen. Overall, there was a striking increase in the presence of CD69 hi GZMB + perforin + CAR-Ts in sub-island i-iia (Fig. 5D) . These data showed that the recognition of RBD peptides by CAR-Ts induced a detectable increase in the expression of GZMB and perforin within a subset of CD69 high expressing CAR-Ts.

A second mechanism of cytolytic mediated killing involves Fas ligand (FasL) (Fig. 6 ). FasL is a TNF superfamily member that binds to the Fas receptor on target cells leading to their apoptosis and death (Russell and Ley, 2002) .Each CR3022 CAR-T increased FasL expression upon incubation with 293-ACE2-RBD cells (Fig. 6A) . In this case, the CR3022-IgG4-28Z CAR-T showed the greatest increase. viSNE analysis showed that FasL was broadly expressed on the majority of CAR-Ts that seen with the other markers (Fig. 6B) . As in the case of CD69, three islands of cells could be defined based on expression (islands i,ii,iii). Unlike for CD69, an increase in FasL was observed (albeit to a lesser extent) in both islands i and ii. The increase in the positive signal in island ii was accompanied by the loss of FasL negative cells (see dark blue), as most evident in the viSNE patterns for the CR3022-IgG4-28Z CAR-Ts. As negative controls, the incubation of CAR-Ts with soluble RBD peptide without 293-ACE2 cells, or the incubation of Flag-28Z cells with 293-ACE2 or J o u r n a l P r e -p r o o f 293-ACE2-RBD showed background staining (upper panels). This indicated that SARS-CoV-2 recognition led to an increase in FasL on a broader population of cells than observed for CD69 ( Fig.   6B, C) . As an alternate system, we also assessed changes in FasL expression in response to NIH/3T3 cells that had been stably transduced to express the S1 peptide (Fig. 6D) . In this case, CR3022-8a-28Z cells also showed a broad increase in FasL expression. These data showed that the recognition of the RBD peptide or the S1 protein on target cells induced the expression of FasL, and that the pattern of induced expression was broader than seen with the expression of CD69, IFNγ or GZMB/perforin. Given this, we next assessed the importance of FasL expression to the killing of RBD-coated cells by adding anti-FasL blocking antibodies to the killing assay (Fig. 6E) . CR3022-28Z, CR3022-8a-28Z and CR3022-IgG4-28Z CAR-T cells were incubated with 293-ACE2-RBD cells in the presence or absence of anti-FasL blocking mAbs, #100419 or #NOK-1, for 5 hours prior to and during the killing assay. NOK-1 has been previously reported to block cell mediated killing (Kayagaki et al., 1995) . A minor reduction in the killing was observed in some ratios of effector to target cells for CR3022-28Z, and CR3022-8a-28Z CAR-Ts; however, the patterns were not consistent. No statistically significant effect was observed on the killing by CR3022-IgG4-28Z CAR-T cells. From these data, we observed that the FasL pathway does not play a major role in the killing of RBDcoated ACE2-expressing cells in our systems.

Lastly, it was important to assess whether CAR-Ts could elicit the killing of targets in vivo in mice (Fig. 7) . For this, we injected a mixture of 2×10 6 NIH/3T3-S1 cells and 4×10 6 CR3014-28Z/ CR3022-28Z CAR-T cells to NOD-SCID IL2Rγ null mice via the intraperitoneal route. The NIH/3T3-S1 cells, in addition to expressing S1 from SARS-CoV-2, express luciferase, and the presence of NIH/3T3-S1 cells can be assessed by injecting D-luciferin. For analysis, bioluminescence images were acquired at 24 h after injection of the cells by administering D-luciferin intraperitoneally (i.p.).

We found that the adoptive transfer of CR3022-28Z reduced the presence of target cells in mice ( Fig. 7A) . While injection with NIH/3T3-S1 cells alone resulted in nearly 4 x 10 9 Luminescence (p/s), injection of NIH/3T3-S1 cells with CR3022-28Z CAR-T cells reduced the luminescence measurement to <1x 10 9 , and CR3014-28Z CAR-T cells had no effect on the presence of the target (Fig. 7B) . In comparison to the untreated samples, the CR3022-28Z reduced the presence of NIH/3T3-S1 cells (i.e. luminescence) by 80%. However, relative to the CR3014-28Z, the luminescence was reduced by 60%. There was a loss of signal in 5/8 mice (shown for 2/3 mice).

Overall, these data confirm that CAR-T cells also are capable of killing S1 expressing cells in vivo in mice.

We next assessed whether the SARS-CoV-2 CAR-Ts could also block viral entry (SFig. 7).

We expected that the efficiency of the blockade would be low given the difficulty in having cells compete for smaller-scale protein-protein interactions. Recombinant pseudo-typed VSV particles containing SARS-CoV-2 spike protein were used to mimic SARS-CoV-2 cell infection and cell entry.

The SARS-CoV-2 pseudo-virus particles encode DsRed in the virus genome. DsRed was strongly expressed after the SARS-CoV-2 pseudo-virus entry into ACE2-expressing cells (Millet et al., 2019) .

From this, using SARS-CoV-2 as a control with an infection rate of 60%, we observed that coincubation with CAR-Ts expressing the various constructs reduced viral entry in response to different ratios of T-cells to target. As expected, the efficacy of blockade was low and observed for bothCR3014 and CR3022 based CAR-Ts (SFig. 7). Both Flag-28z and CR3014-28Z reduced binding to the same degree as CAR-T's expressing specific receptors. Overall, the data showed that CAR-Ts are unlikely to sterically block viral entry into cells, but rather limit viral infection, as seen in the case of most viral infections by mediating CTL killing responses against infected cells expressing viral antigens (Moskophidis and Kioussis, 1998) .

Given the ongoing threat of SARS-CoV-2 and the uncertainties related to the long-term efficacy of vaccines against new variants of the virus, new therapeutic approaches may be needed.

The development of CAR therapy has been proven effective in the treatment of various types of cancers (Kawalekar et al., 2016; Posey et al., 2016) . In this study, we show that it is possible to generate CAR-T cells capable of responding to the SARS-CoV-2 and to elicit the in vitro and in vivo killing of cells loaded with RBD/S1 peptides or which express the S1 protein. Our findings outline the potential use of anti-SARS-CoV-2 CAR-Ts as a therapeutic option against COVID-19.

CR3022 based CAR-Ts were stimulated by the recognition of the RBD peptide as shown by the increased expression of CD69 and the phosphorylation of ribosomal S6, a key regulator of metabolism, translation, and cell division (Roux et al., 2007) . CD69 expression was induced in a peptide concentration-dependent manner, with responses to cells that had been loaded with a peptide-concentrations as low as 10ng/ml. This denotes a remarkable sensitivity to the peptide.

CD69 expression also promotes the retention of T-cells in the lymphoid organs (Cibrian and Sanchez-Madrid, 2017 ) and serves as a marker for resident memory T cells (TRMs) (Osborn et al., 2019; Ziegler et al., 1994) . In this way, the increased CD69 expression on CAR-Ts may alter their residency for enhanced responses against SARS-CoV-2 infected cells.

Exposure to 293-ACE2-RBD cells also potently downregulated CARs from the surface of CAR-Ts. This property has been previously reported for CD19-CARs and is another measure of receptor-mediated engagement (Monjas et al., 2004; San Jose et al., 2000; Schneider et al., 1999) . In this manner, the level of CAR downregulation inversely mirrored the effect of different peptide concentrations on CD69 expression. While confirming that CAR-Ts were responsive to the RBD peptide, the loss of the surface CAR might ultimately limit the longevity of responses against targets as seen in tumor models .

Importantly, SARS-CoV-2 CAR-Ts were cytolytic in the specific killing of target cells loaded with either the RBD peptide, S1 peptide or which express the S1 protein. Specificity was seen by the fact that CR3014 based CAR-Ts failed to kill SARS Cov-2 expressing target cells. In keeping with killing, time-lapse microscopy showed the formation of multi-cellular CAR-T clusters around single target cells. Further, CAR-Ts with different sized hinge regions varied in the efficacy of killing where the IgG4 hinge CAR-T gave the most consistent results in the killing of targets. However, these differences appeared to vary depending on the mode of RBD or S1

presentation. For example, the IgG4 hinge CAR-Ts predominated in response to RBD peptide loaded on 293-ACE cells, while CD28 and IgG4 hinge CAR-Ts were most effective in response to S1 peptide presented on the surface of 3T3 cells. The different hinge regions may therefore affect the ability of CARs to bind and respond to peptides depending on their mode of presentation. By contrast, we did not observe blockade of viral entry into cells based on the use of recombinant pseudo-typed VSV particles containing SARS-CoV-2 spike protein. These were used to mimic SARS-CoV-2 cell infection and cell entry. CAR-Ts are therefore unlikely to sterically block viral entry into cells, but rather limit viral infection in a classic fashion involving CTL-like killing of infected cells expressing viral antigens (Moskophidis and Kioussis, 1998; Rouse and Sehrawat, 2010) .

The extent of SARS-CoV-2 viral peptide antigen expression during infection remains to be established. Various labs have shown that COVID-19 is accompanied by a robust induction of CD4 and CD8 responses against a variety of SARS-CoV-2 peptide antigens Meckiff et al., 2020; Premkumar et al., 2020; Rydyznski Moderbacher et al., 2020; . Given that CD4 and CD8 T-cells are generated by the presentation of peptide antigens, these findings clearly show that peptides derived from various regions of SARS-CoV-2 are presented during infection. The same peptides could be targeted by CAR-Ts.

Further, mass-spectrometry has detected SARS-CoV-2 virus-derived peptides in patients (Nikolaev et al., 2020) ,while SARS-CoV-2 infected cells undergo syncytia formation of ACE2expressing cells, which can be facilitated by antigen recognition (Buchrieser et al., 2021) .

In terms of mechanism, there are two well-established modes of killing by cytolytic T-cells, one involving Fas-FasL and another perforin/granzymes (Williams and Bevan, 2007) . The loss of perforin and Fas/Fas ligand can cause severe autoimmune and inflammation in mice (Peng et al., 1998; Spielman et al., 1998 ). In our model, the expression of FasL and GZMB/perforin increased in response to RBD presenting cells. However, the blockade of FasL with antibodies had only a weak effect on the killing of targets by the anti-SARS-CoV-2 CAR-Ts and there was low to negligible level of Fas expression on the target cells. The observation points to the GZMB/perforin pathway as a major mechanism by which our anti-SARS-CoV-2 CAR-Ts kill targets. Whether the Fas-FasL pathway may also participate in the killing other target cells remains for future studies.

In this context, the effectors GZMB and perforin were expressed within a relatively small subset of CD69 high expressing anti-SARS-CoV-2 CAR-Ts. Perforin allows for GZMB into the target cell for cell death, although GZMB may also enter via other pathways (Smyth et al., 1996) . While GZMB and perforin were expressed in the same subset, not all cells expressing high levels of CD69 expressed GZMB and perforin. This indicates that factors other than the mere activation of cells influenced whether these effectors were expressed. J o u r n a l P r e -p r o o f By contrast, FasL and IFN-γ were more widely expressed on populations of CAR-Ts. viSNE analysis showed that FasL expression occurred in both CD69 high and intermediate populations, while the increase in IFN-γ tended to be more restricted to the CD69 high population. These differences underscore the heterogeneity in the responses of individual SARS-CoV-2 CAR-Ts. IFN-γ has both anti-viral and immunoregulatory properties (Schroder et al., 2004) and can alter the transcription of multiple genes including major histocompatibility antigens on antigen-presenting cells (Schroder et al., 2004) . Higher levels of type I interferons have also been associated with a lower risk of SARS-CoV-2 infection and amelioration of disease severity (Sui et al., 2021) . IFN-γ also primes alveolar macrophages against secondary bacterial infections which may have relevance to COVID-19 associated pulmonary disease (Yao et al., 2018) . It could also assist by inducing STAT3 activation which can activate GZMB expression for enhanced CTL effector function (Lu et al., 2019) . The secretion of IFN-γ by CAR-T cells would, therefore, be expected to promote these beneficial events during the progression of SARS-CoV-2 infection.

CAR-Ts could be most effective in patients who are immunocompromised or who respond weakly to the virus or vaccines Meckiff et al., 2020; Premkumar et al., 2020; Rydyznski Moderbacher et al., 2020; . Further, they may provide longer term memory responses in patients that fail to develop sufficient memory against vaccines.

CAR-Ts against relapsed ALL cancers have shown sustained remissions for 24 months (Maude et al., 2014) . The therapeutic approach could involve the retroviral transduction of T-cells extracted from patient blood and who are reinfused with CAR-Ts as shown for CD19-CAR-T approaches against cancer (Pfeiffer et al., 2018) . The use of anti-SARS-CoV-2 CAR-Ts may be more costly than vaccination but may provide longer-term protective immunity (Thomas et al., 2006) . One complication may involve the induction of inflammation associated with CAR-T therapy. In this context, CAR-Ts would need to be used carefully in the clinic, possibly before infection by the virus, or following the resolution of inflammatory disease associated with severe COVID-19. In this context, anti-IL-6 receptor antibodies have been successful in treating inflammation associated with the use of CAR-Ts in cancer therapy (Guedan et al., 2019) . Its applicability will need to be assessed in a carefully controlled clinical trial.

During the final preparation of this paper, two groups reported the successful generation of natural killer and macrophage CARs in in vitro assays (Fu et al., 2021; Ma et al., 2021) .

Unlike T-cells of the adaptive immune system, these cells are part of the innate immune system with distinct co-receptors that regulate function. NK cells possess activating receptors and inhibitory receptors that include killer-cell immunoglobulin-like receptors (Vivier et al., 2011) , J o u r n a l P r e -p r o o f while macrophages carry other innate receptors such as Mac1 that help mediate phagocytosis (Galdiero et al., 2013) . The work on these papers was confined to in vitro studies, but, if shown to operate in vivo, as in the case of our CAR-Ts, these reagents could complement our SARS-CoV-2 reactive CAR-T-cell approach. Future studies will be needed to determine the application of CAR therapy to the treatment of COVID-19.

By employing CARs against the RBD or S1, we have documented the successful generation of reactive CAR-Ts with a capacity to kill peptide expressing targets using in vitro and in vivo models. As mentioned, the lab of Sette and others have shown the robust induction of CD4 and CD8 responses during SARS-CoV-2 infection indicating that viral peptide antigens are expressed and presented by cells. The precise nature of the peptides and cells involved during infections is an active area and will be of great utility in designing new cytolytic CAR-Ts against infected cells. In terms of killing, the relative contributions of the perforin-granzyme vs the Fas-FasL effector pathways in different contexts need to be determined. As mentioned, although there was a lack of involvement of FasL in our system, future studies will be needed to explore the participation of FasL and IFN-γ in the different systems involving other cell types and peptides. Further, the behaviour of different CARs in vivo and the relative contribution of CD4 and CD8 CAR-Ts need to be defined as does the longevity of CAR-T immune response involving aspects such as CAR-T memory. Lastly, the degree to which CAR-Ts will control SARS-CoV-2 infections a patient or viral spread in populations remains to be assessed. 

was detected by staining the Flag-tag and the EGFP was used for cell sorting (n=5) (also see SFigure 1, 2) . cells was detected with anti-S1 and anti-RBD antibodies. Data are shown as mean ± SD (N=3). **** represents p < 0.0001 (compared with CR3014-28Z by two-way ANOVA, n=4).

(B) CR3022 antibody blocks CR3022-8a-28Z and CR3022-IgG4-28Z kill RBD coated targets.

293-ACE2-RBD cells were incubated with CR3022, or the isotype control, at 37 0 C for 30min prior to the incubation with CAR-Ts. Data are shown as mean ± SD (N=3). **** represents p < 0.0001.(compared with isotype control groups by paired Student's t-test, two tailed, n=2).

(C) Different CAR-Ts kill targets coated with S1 peptide. Left panel: 293-ACE2 cells were loaded with theS1 peptide followed by washing and incubation with CAR-Ts for 4-5 hours prior to a measure of killing. Right panel: The presence of S1peptides on loaded 293-ACE2 cells was detected with anti-S1 and anti-RBD antibodies. Data are shown as mean ± SD (N=3). **** represents p < 0.0001. (compared with CR3014-28Z by two-way ANOVA, n=3).

(D)Different CAR-Ts kill NIH/3T3 cells expressing the S1 peptide. Lower panel:The S1 overexpressing NIH/3T3 cell were sorted by FACS staining of S1.These cells showed high levels of J o u r n a l P r e -p r o o f anti-S1 staining, while the staining with the CR3022 antibody was lower.Upper panel: S1 expressing NIH/3T3 cells were co-cultured with CAR-Ts for 4-5 hours prior to a measure of killing. Data are shown as mean ± SD (N=3). **** represents p < 0.0001.(compared with CR3014-28Z by two-way ANOVA, n=3) (also see SFigure 6). shown as mean ± SD (N=3). *represents p < 0.05. ** represents p< 0.01. (compared with mouse IgG1 isotype group by paired Student's t-test, two tailed, n=2).

The in vivo elimination of NIH/3T3 cells expressing SARS-CoV-2 S1

(A) Images of NIH/3T3-S1 cells in mice. NIH/3T3-S1 cells express luciferase and the presence of luminescence after D-luciferin injection indicates the presence of NIH/3T3-S1 cells. A mixture of2×10 6 NIH/3T3-S1cells and4×10 6 CR3014-28Z or CR3022-28Z CAR-T cells were injected into NOD-SCID IL2Rγ null mice through the intraperitoneal route. 24h later, Dluciferin was injected and bioluminescence images were acquired. 4-5 mice are shown out of 8 mice per group in total.

Histogram showing the significant reduction of NIH/3T3-S1 cells in vivobyCR3022-8a- that had been pre-incubated with RBD peptide and tracked for 20 hours. EGFP+ CAR-T cells were observed to form clusters with 293-ACE2+RBD cells.

SMovie 3: Panels of time-lapse movies of co-culturing of CAR-Ts with S1 peptide-loaded 293-ACE2 cells, related to Figure 3 . CR3022-8a-28Z CAR-Ts were co-cultured with 293-ACE2 that had been pre-incubated with S1 peptide and tracked for 20 hours. EGFP+ CAR-T cells were observed to form clusters with 293-ACE2+S1 cells.

J o u r n a l P r e -p r o o f

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Dr. Christopher E Rudd (christopher.e.rudd@umontreal.ca).

This unique CAR reagents will be made available upon request.

All datasets in this study have been deposited at Mendeley Data https://data.mendeley.com/datasets/3y3m8btcnk/2 and will be shared further by the lead contact upon request. DOI is listed in the key resources table. Any additional information required to reanalyze the data reported in this paper is available upon request.

Cell Both female and male mice, the age of which range from 9 to 15 weeks old, were included and randomized to treatment groups based on sex, age and weight.

Human blood from healthy donors was provided by HÉMA-QUÉBEC with donors' written informed consent and experiments using human PBMC were approved by the Research Ethics Committee of CIUSSS de l'Est-de-l'Île- de-Montréal (protocol # 2019 de-Montréal (protocol # -1184 .

The 229AA, 99-327, UniProt ID P01861) as described elsewhere (Hudecek et al., 2015) . The whole CAR construct was codon-optimized and synthesized by GeneArt (Thermo Scientific) and sub-cloned into pHIV-EGFP vector between EcoRI and XbaI cloning site.

The lentiviral vector pHIV-EGFP was a kind gift from Bryan Welm& Zena Werb (Addgene # 18121; http://n2t.net/addgene:18121; RRID: Addgene_18121) (Welm et al., 2008) . http://n2t.net/addgene:104833; RRID: Addgene_104833) (Ebinger et al., 2016) . The plasmid pGBW-m4137382, encoding the SARS-CoV-2 surface glycoprotein (Spike) for VSV pseudotyping, was a kind gift from Ginkgo Bioworks (Addgene # 149539;

http://n2t.net/addgene:149539; RRID: Addgene_149539).

293T cells were pre-plated in 6 well plates in 2 ml complete DMEM per well 24h prior to transfection. After being cultured overnight, 3 μg pGBW-m4137382 was mixed with 8 μl X- 

293T cells were co-transfected with CAR-encoding vectors, pMD2.G and psPAX2 by using X-treme GENE HP DNA transfection reagent (Roche) according to the manufacturer's instruction.

After overnight transfection, the supernatant was replaced with fresh RPMI-1640 complete medium.

The supernatant containing lentivirus was harvested at 48 h and 72 h post-transfection and stored at -80℃.

To generate CAR-T cells, 3×10 6 PBMC were resuspended in 1ml X-VIVO15 serum-free medium (Lonza) with soluble 1 μg/ml anti-hCD28 antibody (Clone # 9.3) and seeded into a 24 well plate pre-coated with 2μg/ml anti-hCD3 antibody (Clone # OKT-3). After 72 h of stimulation, cells were washed 2 times, and the medium was exchanged with 2 ml virus supernatant containing 10μg/ml protamine sulfate and spinoculated at 1200g for 60 min at 32℃. After 1 h of incubation at 37℃, the supernatant was replaced with 2 ml fresh X-VIVO15 serum-free medium and cultured for 4 J o u r n a l P r e -p r o o f days before FACS sorting based on EGFP expression. The sorted CAR-T cells were expanded in X-VIVO15 medium with 1000 IU/ml recombinant human IL-2 (Stemcell) and sub-cultured every 2~3 days with fresh media.

To generate CAR-Jurkat, 2×10 5 Jurkat cells were resuspended with 1 ml virus supernatant containing 10 μg/ml protamine sulfate and spinoculated at 1200 g for 60 min at 32℃. After 1 h of incubation at 37℃, supernatant was replaced with 2 ml fresh RPMI-1640 complete medium and the transduced cells were sub-cultured for 3 passages before sorting with cell sorter (SONY SH800) based on EGFP expression.

For flow cytometric surface staining (anti-Flag, CD69 and FasL), CAR-Ts and other cells were incubated with fluorochrome-conjugated antibodies at 4℃ for 30min followed by washing and fixation with 4 percent PFA followed by additional washing and analysis by either FACS Celesta (BD) or Fortessa X-20 (BD) as previously described (Raab et al., 2010) . In certain instances, indirect two step staining was conducted with an unconjugated primary antibody for 30min on ice (anti-S1, anti-RBD) followed by washing and incubation with a conjugated secondary antibody for another 30 min at 4℃and analyzed by FACS. For intracellular staining (IFN-γ, GZMB, perforin, pS6), cells were permeabilized by using the intracellular staining kit 

Three types of in vitro functional assays were conducted. In one case, freshly expanded CAR-Ts (10 6 /cell/ml) were incubated with 293-ACE2-RBD or 293-ACE2 cells (10 6 cells CAR-Ts and 5.0 x 10 5 /ml 293-ACE2 cells) for 20min prior to permeabilization kit (Invitrogen) and staining with phospho-S6 (1:1000 dilution). As a control, phorbol ester (PMA) (Sigma) and ionomycin (Sigma) was also used to stimulate the CAR-T for 20min. In another instance, the same proportions of cells were incubated for 18-20hrs followed by cell permeabilization and staining with anti-GZMB, anti-perforin and anti-IFN-g, or for 24h and stained for CD69 and FasL. In the third in vitro assay, we measured the cytolytic killing of target cells. 293-ACE2 target cells were either left untreated or were coated with the RBD-His (#SPD-C52H3, Acro Biosystems) or S1-His peptides (#S1N-C82E8, Acro Biosystems). For coating the 293-ACE2 cells, 1 μg/ml RBD or S1

protein was added to 1×10 6 /ml cells at 37℃ for 1hr followed by a gentle wash in media before J o u r n a l P r e -p r o o f used in experiments with CAR-Ts. In other experiments, NIH/3T3 cells expressing S1 was also In certain instances, antibodies to the RBD epitope or FasL were used to block the response.

For blocking the RBD epitope, 1 μg/ml RBD protein was added to 1×10 6 /ml 293-ACE2 cells and incubated at 37℃ for 1 h. After that, the cells were washed twice, re-suspended with 400 μl RPMI-1640 medium (5% FBS, phenol red free) and split into two EP tubes equally. 1 μg/ml anti-RBD antibody (clone # CR3022, Abcam) or 1 μg/ml rabbit IgG isotype control antibody (Clone # 60024B, R&D) was added to each tube (5×10 5 293-ACE2-RBD in 200 μl medium), respectively, and incubated at 37℃ for 30 min. Then cells were directly diluted with RPMI-1640 medium to a final volume of 2 ml/tube without wash, and co-cultured with different CAR-T cells at the ratio of 1/24, 1/12, 1/6 and 1/3 in a U-bottom 96-well plate (Corning).

Similarly, for the blockade of FasL, 2 μg/ml anti-hFasL antibody (NOK-1 or 100419) was added to 1×10 6 /ml CAR-T cells, incubated at 37℃ for 1 h and co-cultured with target cells without wash.

5×10 4 293-ACE2-mCherry cells were resuspended with 500 μl RPMI-1640 medium (5% FBS, phenol red free) and pre-plated in a cover-glass bottom dish (SPL life sciences) at 37℃. After being cultured overnight, 1 μg/ml RBD protein was added to cells and incubated at 37℃ for 1 h.

Then 2×10 6 CR3022-8a-28Z-EGFPCAR-T cells were resuspended with 1.5 ml RPMI-1640 medium (5% FBS, phenol red free) and added to the dish for co-culture in an inverted fluorescence microscope with climate control (Zeiss Observer Z1). Images were captured from the beginning of J o u r n a l P r e -p r o o f the co-culture with a 2 min interval for 24h. Videos were exported and analysed by using ZEN Lite software (Zeiss).

Mice were injected i.p. with either 2×10 6 NIH/3T3-S1-Luc cells (NT group) or a combination of 2×10 6 NIH/3T3-S1-Luc cells and CAR-T cells in the ratio of 1/2 premixed in 300 ul of RPMI-1640 medium (CR3014-28z and CR3022-28z groups). At 24 h post-implantation, mice were injected i.p.

with 150 mg/kg RediJect D-Luciferin (PerkinElmer; #770505). Mice were anaesthetized with 2%

isoflurane and transferred to the IVIS Lumina III (PerkinElmer) for in vivo imaging at 10 min postinjection. Mice from three different groups were imaged simultaneously with 20 sec of exposure.

Bioluminescence images were overlapped with bright field images of mice and displayed in the same intensity range. Images were acquired and analyzed by using Aura Imaging Software (Spectral Instruments Imaging). The total radiance (Photon/s and counts) was measured and calculated for each region of interest (ROI).

The n represents individual donors from a random pool of donors provided by the blood service Hema-Quebec (Quebec). The response of CAR-Ts was compared from one donor to another. This measure applied to all figures in the paper. Although CAR-T cell numbers were expanded in vitro from a given individual donor, all cells were used at a single time from the individual donor for cytolytic killing assays and flow cytometry. No repeat experiments from individual donors was done due to the lack of repeat access to individual donors. Statistical analysis was performed by using GraphPad Prism ® software v8.0 (GraphPad). Two-tailed Student's t-test was used to compare two normally distributed independent groups with continuous endpoints. The one-way ANOVA was applied when more than two groups were compared and the two-way ANOVA was applied when there are two independent variables. Dunnett's post hoc test was used for multiple comparisons. All experiments were repeated at least two times, and all experimental data in figures and texts are shown as the mean ± standard deviation. p values less than 0.05 was considered statistically significant. 

TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection

Cellular events in the lymph node and lung of mice with influenza. Consequences of depleting CD4+ T cells

SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection

SARS-CoV-2 Vaccines: Status Report

Deployment of convalescent plasma for the prevention and treatment of COVID-19

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19

Syncytia formation by SARS-CoV-2-infected cells

Prediction of SARS-CoV-2 epitopes across 9360 HLA class I alleles

Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells

Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation

CD69: from activation marker to metabolic

Apoptosis-Induced T Cell Lymphopenia Is Related to COVID-19 Severity

Characterization of Rare, Dormant, and Therapy-Resistant Cells in Acute Lymphoblastic Leukemia

Mechanism of protective immunity against influenza virus infection in mice without antibodies

CAR Macrophages for SARS-CoV-2 Immunotherapy

Tumor associated macrophages and neutrophils in tumor progression

Resistance to and recovery from lethal influenza virus infection in B lymphocyte-deficient mice

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Generation of effector T cells expressing chimeric T cell receptor with antibody type-specificity

Emerging Cellular Therapies for Cancer

A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Mass Spectrometric Identification of SARS-CoV-2 Proteins from Gargle Solution Samples of COVID-19 Patients

The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways

Treatment options for COVID-19: The reality and challenges

Redirecting T-cell specificity by introducing a tumorspecific chimeric antigen receptor

Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells

Metalloproteinase-mediated release of human Fas ligand

T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice

Delivery and therapeutic potential of human granzyme B

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Type I interferon suppresses tumor growth through activating the STAT3-granzyme B pathway in tumor-infiltrating cytotoxic T lymphocytes

CAR-NK Cells Effectively Target SARS-CoV-2-Spike-Expressing Cell Lines In Vitro

Chimeric antigen receptor T cells for sustained remissions in leukemia

Making Better Chimeric Antigen Receptors for Adoptive Tcell Therapy

CD8 T cell exhaustion during chronic viral infection and cancer

Recognition of influenza A virus nucleoprotein by human cytotoxic T lymphocytes

Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4(+) T Cells in COVID-19

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting

Engaged and bystander T cell receptors are down-modulated by different endocytotic pathways

Contribution of virus-specific CD8+ cytotoxic T cells to

Mass-Spectrometric Detection of SARS-CoV-2 Virus in Scrapings of the Epithelium of the Nasopharynx of Infected Patients via Nucleocapsid N Protein

Central memory CD8+ T cells become CD69+ tissue-residents during viral skin infection independent of CD62L-mediated lymph node surveillance

ACE-2-interacting Domain of SARS-CoV-2 (AIDS) Peptide Suppresses Inflammation to Reduce Fever and Protect Lungs and Heart in Mice: Implications for COVID-19 Therapy

Perforin protects against autoimmunity in lupus-prone mice

Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19

In vivo generation of human CD19-CAR T cells results in B-cell depletion and signs of cytokine release syndrome

Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma

The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients

T cell receptor "inside-out" pathway via signaling module SKAP1-RapL regulates T cell motility and interactions in lymph nodes

Immunity and immunopathology to viruses: what decides the outcome?

RAS/ERK signaling promotes site-specific ribosomal protein S6 RSK and stimulates cap-dependent translation

Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence

Lymphocyte-mediated cytotoxicity

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

The promise and potential pitfalls of chimeric antigen receptors

Triggering the TCR complex causes the downregulation of nonengaged receptors by a signal transductiondependent mechanism

COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?

Cytolytic T lymphocyte-associated antigen-4 and the TCR zeta/CD3 complex, but not CD28, interact with clathrin adaptor complexes AP-1 and AP-2

Regulation of interferon-gamma during innate and adaptive immune responses

Interferon-gamma: an overview of signals, mechanisms and functions

CAR T Cells Beyond Cancer: Hope for Immunomodulatory Therapy of Infectious Diseases

Mesenchymal Stem Cell Infusion Shows Promise for Combating Coronavirus (COVID-19)-Induced Pneumonia

Xenospecific cytotoxic T lymphocytes use perforin-and Fas-mediated lytic pathways

Immunological and inflammatory profiles in mild and severe cases of COVID-19

Perforin/Fas-ligand double deficiency is associated with macrophage expansion and severe pancreatitis

Potential SARS-CoV-2 Immune Correlates of Protection in Infection and Vaccine Immunization

The trinity of COVID-19: immunity, inflammation and intervention

Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants

IL-6 inhibition in the treatment of COVID-19: A meta-analysis and meta-regression

Cell-mediated protection in influenza infection

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirusspecific human monoclonal antibody

CD8+ T cells clear influenza virus by perforin or Fas-dependent processes

Selective CD8 cell reduction by SARS-CoV-2 is associated with a worse prognosis and systemic inflammation in COVID-19 patients

Innate or adaptive immunity? The example of natural killer cells

Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome

Effector and memory CTL differentiation

SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects

Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods

Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines

Induction of Autonomous Memory Alveolar Macrophages Requires T Cell Help and Is Critical to Trained Immunity

A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV

The activation antigen CD69

Anti-Flag staining shows the surface expression of the Flag-tagged CARs in islands i, ii and iii (following expansion and prior to incubation with 293-ACE2 cells), while GFP shows the expression of EGFP by the pHIV bicistronic lentiviral

SFigure 2: CD4 and CD8 CAR-Ts generated within the lentiviral transduced human peripheral Tcell population, related to Figure 1B. Flow cytometric staining with anti-CD4 and anti-CD8 shows similar proportions of CD8+ and CD4+ cells amongst the CR3022-28Z

Flow cytometric profile of human ACE2 expression on 293 cells, related to Figure 1C. 293 cells were transduced to stably express the hACE2 receptor

Changes in the expression of CD69 in subsets of CAR-Ts following incubation with 293-ACE2 or 293-ACE2-RBD cells, related to Figure 1E. From Figure 1e, the viSNE is subdivided into Islands i ii and and iii based on the surface expression of the activation marker CD69. Fig. 1e, right panels shows the changes in expression for island i. SFigure 4 shows that change in the percent representation amongst CAR-Ts for islands ii and and iii

MFI changes in expression (Panel B)

related to Figure 1. Induction of CD69 on Jurkat cells expressing different CARs in response to Vero cells loaded with RBD peptide. Data are shown as mean ± SD (n=3)

related to Figure 2. The killing of 293-ACE2 target cells that had been precoated with either the RBD (upper panels: donors B and C) or S1 peptide (lower panels: donors A and E)

Recombinant pseudotyped viral particles containing SARS-CoV-2 spike protein were used to mimic SARS-CoV-2 cell infection and cell entry. The SARS-CoV-2 pseudo-virus particles encode DsRed in the viral genome. The DsRed gene will be strongly expressed after the SARS-CoV-2 pseudo-virus entry into ACE2-expressing cells

SMovies SMovie 1: Panels of time-lapse movies of co-culturing of CAR-Ts with 293-ACE2 cells, related to Figure 3. CR3022-8a-28Z CAR-Ts were co-cultured with the 293-ACE2 cells and tracked for 20 hours

SMovie 2: Panels of time-lapse movies of co-culturing of CAR-Ts with RBD peptide loaded 293-ACE2 cells, related to Figure 3. CR3022-8a-28Z CAR-Ts were co-cultured with 293-ACE2 that had been pre-incubated with RBD peptide and tracked for 20 hours

SMovie 3: Panels of time-lapse movies of co-culturing of CAR-Ts with S1 peptide loaded

Cytolytic CAR-T cells can be successfully developed against SARS-CoV-2

CAR-T binding to RBD peptide induced effectors IFN-γ, GZMB and FasL 3) CAR-Ts with different hinge regions showed differences in target killing

SAR-CoV2 CAR-Ts show successful in vivo killing of S1-expressing cells in mice

**** ** ****